Literature DB >> 2977086

Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia.

R Schwarcz1, C A Tamminga, R Kurlan, I Shoulson.   

Abstract

The concentration of the endogenous excitotoxin quinolinic acid was determined in the cerebrospinal fluid of drug-free patients suffering from Huntington's disease or schizophrenia (control group). In both diseases, quinolinic acid concentrations were highly variable (less than 4-48 nM) but the mean levels for each disease group were not significantly different from each other or from the quinolinic acid concentration of normal cerebrospinal fluid. Analysis of steady-state cerebrospinal fluid quinolinic acid concentration is unlikely to be of value as a diagnostic tool in Huntington's disease.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2977086     DOI： 10.1002/ana.410240417

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  17 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

2.  Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.

Authors:  M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt
Journal:  Neurochem Res       Date:  2016-05-10       Impact factor: 3.996

3.  Immune-mediated mechanisms in multiple sclerosis.

Authors:  D Fuchs; G Reibnegger; E R Werner; H Wachter
Journal:  J Neurol       Date:  1990-04       Impact factor: 4.849

Review 4.  Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

Authors:  Ikwunga Wonodi; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2010-02-10       Impact factor: 9.306

5.  Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease.

Authors:  N R Swerdlow; J Paulsen; D L Braff; N Butters; M A Geyer; M R Swenson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

6.  Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury.

Authors:  R Töpper; J Gehrmann; R Banati; M Schwarz; F Block; J Noth; G W Kreutzberg
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 7.  Inflammatory mediators as biomarkers in brain disorders.

Authors:  Domenico Nuzzo; Pasquale Picone; Luca Caruana; Sonya Vasto; Annalisa Barera; Calogero Caruso; Marta Di Carlo
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 8.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

9.  Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.

Authors:  Eniko Vamos; Krisztina Voros; Denes Zadori; Laszlo Vecsei; Peter Klivenyi
Journal:  J Neural Transm (Vienna)       Date:  2009-06-24       Impact factor: 3.575

Review 10.  The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects.

Authors:  K McCormack
Journal:  Drugs       Date:  1994       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.